Artículos por temáticas

Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies

Chen Y, Fu AKY, Ip NY.

Pharmacol Ther. 2019 Mar;195:186-198. doi: 10.1016/j.pharmthera.2018.11.006. Epub 2018 Nov 12.

Broadening the definition of brain insulin resistance in aging and Alzheimer's disease

Frazier HN, Ghoweri AO, Anderson KL, Lin RL, Porter NM, Thibault O.

Exp Neurol. 2019 Mar;313:79-87. doi: 10.1016/j.expneurol.2018.12.007. Epub 2018 Dec 18.

Olfactory and other sensory impairments in Alzheimer disease

Murphy C.

Nat Rev Neurol. 2019 Jan;15(1):11-24. doi: 10.1038/s41582-018-0097-5.

Bottom-up gamma maintenance in various disorders

Garcia-Rill E, Mahaffey S, Hyde JR, Urbano FJ.

Neurobiol Dis. 2019 Aug;128:31-39. doi: 10.1016/j.nbd.2018.01.010. Epub 2018 Jan 17.

Early compensatory responses against neuronal injury: A new therapeutic window of opportunity for Alzheimer's Disease?

Merlo S, Spampinato SF, Sortino MA.

CNS Neurosci Ther. 2019 Jan;25(1):5-13. doi: 10.1111/cns.13050. Epub 2018 Aug 12.

Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology

La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, Doré V, Grinberg LT, Huang E, Hwang JH, Ikonomovic MD, Jack C Jr, Jagust WJ, Jin LW, Klunk WE, Kofler J, Lesman-Segev OH, Lockhart SN, Low

Alzheimers Dement. 2019 Feb;15(2):205-216. doi: 10.1016/j.jalz.2018.09.001. Epub 2018 Oct 19.

Systems biology and gene networks in Alzheimer's disease

Wang ZT, Tan CC, Tan L, Yu JT.

Neurosci Biobehav Rev. 2019 Jan;96:31-44. doi: 10.1016/j.neubiorev.2018.11.007. Epub 2018 Nov 20.

Seizure in Alzheimer's Disease: An Underestimated Phenomenon

Asadollahi M, Atazadeh M, Noroozian M.

Am J Alzheimers Dis Other Demen. 2019 Mar;34(2):81-88. doi: 10.1177/1533317518813551. Epub 2018 Dec 30.

Neuroprotective Effects of Flavonoid Compounds on Neuronal Death Associated to Alzheimer's Disease

Sureda A, Capó X, Tejada S.

Curr Med Chem. 2019;26(27):5124-5136. doi: 10.2174/0929867325666171226103237.

Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research

Hampel H, Mesulam MM, Cuello AC, Khachaturian AS, Vergallo A, Farlow MR, Snyder PJ, Giacobini E, Khachaturian ZS.

J Prev Alzheimers Dis. 2019;6(1):2-15. doi: 10.14283/jpad.2018.43.

Dysfunctional γ-Secretase in Familial Alzheimer's Disease

Wolfe MS.

Neurochem Res. 2019 Jan;44(1):5-11. doi: 10.1007/s11064-018-2511-1. Epub 2018 Apr 4.

Connecting the Dots: Linking the Biochemical to Morphological Transitions in Alzheimer's Disease

Baig AM.

ACS Chem Neurosci. 2019 Jan 16;10(1):21-24. doi: 10.1021/acschemneuro.8b00409. Epub 2018 Aug 30.

Neuroendocrine-Metabolic Dysfunction and Sleep Disturbances in Neurodegenerative Disorders: Focus on Alzheimer's Disease and Melatonin

Spinedi E, Cardinali DP.

Neuroendocrinology. 2019;108(4):354-364. doi: 10.1159/000494889. Epub 2018 Oct 28.

Vitamin D basis of Alzheimer's disease: from genetics to biomarkers

Dursun E, Gezen-Ak D.

Hormones (Athens). 2019 Mar;18(1):7-15. doi: 10.1007/s42000-018-0086-5. Epub 2018 Nov 27.

Apolipoprotein E4 genotype in combination with poor metabolic profile is associated with reduced cognitive performance in healthy postmenopausal women: implications for late onset Alzheimer's disease

Karim R, Koc M, Rettberg JR, Hodis HN, Henderson VW, St John JA, Allayee H, Brinton RD, Mack WJ.

Menopause. 2019 Jan;26(1):7-15. doi: 10.1097/GME.0000000000001160.